Does CARFILZOMIB Cause Hypertransaminasaemia? 6 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Hypertransaminasaemia have been filed in association with CARFILZOMIB (KYPROLIS). This represents 0.0% of all adverse event reports for CARFILZOMIB.
6
Reports of Hypertransaminasaemia with CARFILZOMIB
0.0%
of all CARFILZOMIB reports
0
Deaths
2
Hospitalizations
How Dangerous Is Hypertransaminasaemia From CARFILZOMIB?
Of the 6 reports, 2 (33.3%) required hospitalization.
Is Hypertransaminasaemia Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for CARFILZOMIB. However, 6 reports have been filed with the FAERS database.
What Other Side Effects Does CARFILZOMIB Cause?
Plasma cell myeloma (2,238)
Off label use (2,120)
Death (1,442)
Thrombocytopenia (1,265)
Fatigue (1,048)
Pneumonia (1,016)
Pyrexia (969)
Anaemia (910)
Dyspnoea (881)
Neutropenia (874)
What Other Drugs Cause Hypertransaminasaemia?
METHOTREXATE (436)
ACETAMINOPHEN (326)
PACLITAXEL (318)
CARBOPLATIN (304)
PEMBROLIZUMAB (231)
ATORVASTATIN (207)
CYCLOPHOSPHAMIDE (202)
PREDNISONE (198)
GEMCITABINE (196)
DEXAMETHASONE (169)
Which CARFILZOMIB Alternatives Have Lower Hypertransaminasaemia Risk?
CARFILZOMIB vs CARGLUMIC ACID
CARFILZOMIB vs CARIPRAZINE
CARFILZOMIB vs CARISOPRODOL
CARFILZOMIB vs CARMUSTINE
CARFILZOMIB vs CARTEOLOL